Key Takeaway
Ever wonder how much medication is actually active in your system right now? A GLP-1 medication level estimator shows you an approximation of your current blood concentration based on your dose, medication type, and when you last injected.
Ever wonder how much medication is actually active in your system right now? A GLP-1 medication level estimator shows you an approximation of your current blood concentration based on your dose, medication type, and when you last injected. It helps you understand why you feel different at various points during the week.
Key Takeaways: - Learn how glp-1 medication levels work - Using the Medication Level Estimator - Understand what your medication levels tell you - Practical Applications of Knowing Your Levels
This tool isn't a replacement for blood work. But it gives you a useful picture of how your medication levels rise and fall between injections. That knowledge helps you plan meals, manage side effects, and have better conversations with your provider.
How GLP-1 Medication Levels Work
Every medication has a half-life. This is the time it takes for half of the drug to leave your body. Understanding half-life explains why GLP-1 medications are dosed weekly and why you may feel different on day one versus day six.
Semaglutide has a half-life of approximately 7 days (168 hours). 7 days after your injection, roughly half the medication remains in your system. After another 7 days, about 25 percent remains. This long half-life is what allows weekly dosing.
Tirzepatide has a slightly shorter half-life of about 5 days (120 hours). It still works as a weekly injection, but you may notice a slight dip in appetite suppression toward the end of the week compared to semaglutide.
When you take weekly injections over time, the medication builds up in your system. This is called steady state. It typically takes 4 to 5 half-lives to reach steady state. For semaglutide, that means about 4 to 5 weeks at any given dose. This is one reason why moves in four-week steps.
"What makes tirzepatide particularly interesting is the dual GIP/GLP-1 mechanism. We're seeing that GIP receptor activation appears to amplify the metabolic effects in ways we didn't fully anticipate from the preclinical data.") Dr. Ania Jastreboff, MD, PhD, Yale School of Medicine, lead author of SURMOUNT-1[1]
The estimator uses these pharmacokinetic principles to model your current level. It accounts for accumulated doses and the natural decay curve between injections.
Free Download: Dose Conversion Table A visual reference showing medication level curves for common GLP-1 doses, including peak and trough levels throughout the week. Get yours free (we'll email it to you instantly.
[Download Now]
Using the Medication Level Estimator
The tool requires three simple inputs. Enter them and get an instant visualization of your estimated medication curve.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Select your medication. Choose semaglutide or tirzepatide. Each has different pharmacokinetic properties that affect how levels rise and fall throughout the week.
Enter your current dose. This is your weekly injection dose in milligrams. The calculator uses this to model the peak concentration after injection and the gradual decline over the following days.
Enter your last injection date and time. This is the key variable. The calculator determines where you're on the medication curve right now. Are you at peak levels (12 to 36 hours post-injection)? Or approaching your trough (day 6 or 7)?
The output shows a visual curve of your estimated levels over the past week and the upcoming week. It highlights your current position on the curve and indicates whether you're near peak, mid-range, or trough levels.
This visualization pairs well with the , which tracks your injection history and can show medication level trends over time. Seeing how your levels align with your appetite, energy, and side effects creates valuable patterns.
What Your Medication Levels Tell You
Understanding where you're on the medication curve helps explain day-to-day variations in how you feel.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Peak levels (12-36 hours post-injection) are when the medication concentration is highest. You may notice the strongest appetite suppression during this window. Some people also experience the most side effects here, particularly nausea. If side effects bother you, try injecting before bed so the peak occurs while you sleep.
Mid-range levels (days 2-4) represent the therapeutic sweet spot for many people. Appetite suppression remains strong, but peak-related side effects have faded. Most people feel their best during this window.
Trough levels (days 5-7) are when medication concentration drops to its lowest point before the next injection. Some people notice increased appetite or cravings during this period. If your trough symptoms are significant, it may indicate you need a higher dose. Discuss this with your provider.
Steady state changes are worth tracking too. When you increase your dose during , it takes 4 to 5 weeks for the new steady state to establish. Side effects during dose increases are partly due to the rising baseline level.
The estimator helps you see these patterns clearly rather than guessing why yesterday felt different from today.
Practical Applications of Knowing Your Levels
This knowledge isn't just academic. It has real-world applications for managing your GLP-1 treatment effectively.
Meal planning around your curve. If you know your appetite suppression peaks on days 1 and 2, plan your highest-protein meals for days 5 through 7 when hunger may increase. This helps you maintain consistent nutrition throughout the week.
Side effect management. If nausea reliably hits during your peak window, schedule lighter meals and extra hydration during that period. Knowing it's temporary and predictable makes it easier to manage.
Exercise timing. Some people feel more energetic at certain points in their medication cycle. Tracking your levels alongside your workout performance can reveal your optimal training days.
Provider conversations. Showing your provider your medication level data alongside your symptom log creates a richer picture. It helps them make more informed decisions about dosing adjustments. The generates reports you can share during consultations.
Travel planning. If you're traveling across time zones, the estimator helps you understand how shifting your injection timing affects your levels. Your provider can advise on the best approach for maintaining consistent coverage.
For more information on managing your GLP-1 protocol, read our .
Frequently Asked Questions
How accurate is the medication level estimator?
The estimator uses published pharmacokinetic data to model typical medication behavior. Individual factors like metabolism, body composition, and kidney function affect actual levels. Think of it as a helpful approximation rather than a precise lab measurement.
Why do I feel hungrier at the end of the week before my next injection?
Your medication level drops to its lowest point (trough) in the days before your next injection. This natural dip can reduce appetite suppression. If end-of-week hunger significantly impacts your progress, talk to your provider about dosing adjustments.
Does the estimator work for compounded semaglutide?
Yes. Compounded semaglutide contains compounded formulations of the active ingredient and follows the same pharmacokinetic profile. The half-life and absorption characteristics are consistent regardless of whether the medication comes from a brand manufacturer or a licensed compounding pharmacy.
How long until my medication reaches steady state?
Steady state takes about 4 to 5 half-lives. For semaglutide, that's roughly 4 to 5 weeks at a consistent dose. For tirzepatide, it's about 3 to 4 weeks. Each time you change doses during titration, the clock resets for the new steady state.
Should I adjust my injection day based on the level estimator?
Don't change your injection schedule without consulting your provider. Consistency is key for maintaining steady medication levels. If you notice problematic patterns in your level curve, bring this data to your provider and discuss options together.
Start your treatment Today
Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you) consultations are free and confidential.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
The information in this article is intended for educational use only and shouldn't be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.
Last updated: 2026-03-24